emactuzumab   

GtoPdb Ligand ID: 8944

Synonyms: RG7155 | RO5509554
Compound class: Antibody
Comment: Emactuzumab is a humanized, IgG1κ anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody, being investigated for its anti-cancer potential.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Peptide sequence analysis using the heavy and light chain variable regions of emactuzumab reveals 100% matches to sequences 39 and 40 respectively from patent US20110165156 [2]. These two sequences belong to the clone named hMab 2F11-e7 (or simply 2F11) in the patent document.

In 2018 Roche terminated their emactuzumab development programme. In August 2020 they announced that they were licensing emactuzumab to Celleron Therapeutics who intent to progress the drug as a treatment for diffuse tenosynovial giant cell tumours (TGCT), for which Roche have alreaady published efficacy [7], TGCT is driven by cells that overproduce the CSF1 protein which attracts the macrophages that ultimately cause the inflammatory damage that characterises the disease.
Classification
Compound class Antibody
International Nonproprietary Names
INN number INN
9951 emactuzumab
Synonyms
RG7155 | RO5509554
Database Links
Specialist databases
IMGT/mAb-DB 501
Other databases
GtoPdb PubChem SID 310264725
Search PubMed clinical trials emactuzumab
Search PubMed titles emactuzumab
Search PubMed titles/abstracts emactuzumab